NCT05684146Unknown2 期
Protect the Head to Head: A Safety and Efficacy Assessment of the Emboliner Embolic Protection Device
Emboline3 个研究点 分布在 1 个国家目标入组 540 人开始时间: 2023年5月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 540
- 试验地点
- 3
- 主要终点
- Non-inferiority
研究概览
简要总结
Prospective, randomized, open label, multicenter, 2-arm, safety and efficacy study
详细描述
Prospective, randomized, open label, multicenter, 2-arm, safety and efficacy study to demonstrate safety and effectiveness based on non-inferiority of the study device (Emboliner EPD) compared to the control device (Sentinel CPS) in terms of a 30-day composite major adverse cardiac and cerebrovascular events (MACCE) rate - defined as all death, stroke and Stage 3 acute kidney injury - evaluated on a per-patient basis, post-TAVR procedures
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible for treatment for symptomatic severe aortic stenosis using a FDA-approved TAVR valve according to current guidelines
- •Consented to the TAVR procedure
- •Subject and physician agree that subject will return for required post-procedure follow-up
- •Willing to participate in study and provide signed EC/IRB-approved informed consent
- •Eighteen (18) years or older at the time of consent
排除标准
- •Not undergoing a planned TAVR via transfemoral access
- •Severe allergy or hypersensitivity to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, nitinol, and/or contrast agents that cannot be pre-medicated
- •Uncorrected bleeding disorder
- •Hypercoagulation status that cannot be corrected by additional peri-procedural heparin
- •Myocardial infarction (MI) diagnosis <30 days prior to study procedure
- •History of substance abuse that may cause non-compliance with the protocol or confound the data interpretation
- •Cardiogenic shock, hemodynamic instability requiring inotropic support or mechanical heart assistance, or severe hypotension (systolic blood pressure <90 mmHg) at time of screening
- •History of a stroke < 180 days prior to study procedure
- •Active peptic ulcer or history of upper gastrointestinal (GI) bleeding < 90 days prior to study procedure
- •Congenital unicuspid aortic valve
- •Porcelain aorta, asymmetrical or sharp aortic calcifications, severe aortic tortuosity, shaggy aorta or mobile atheroma in the arch
- •Pre-existing prosthetic heart valve in any position, prosthetic ring, or severe (greater than 3+) mitral insufficiency
- •Current leukopenia, acute anemia, thrombocytopenia, history of chronic bleeding diathesis, or coagulopathy that requires treatment
- •Hypertrophic cardiomyopathy with or without obstruction
- •Left ventricular ejection fraction (LVEF) ≤20%
- •Echocardiographic evidence of intracardiac or aortic mass, thrombus, or vegetation
- •Active infection or endocarditis
- •Neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults
- •Carotid stent placement or endarterectomy performed <180 days prior to study procedure.
- •Severe renal insufficiency (creatinine >3.0 mg/dL or GFR <30 mL/min) or patient on dialysis
- •Planned treatment with another investigational device or procedure during the study period
- •Balloon valvuloplasty (BAV) within 30 days of the procedure
- •Any planned surgical or interventional cardiac procedure (e.g., concurrent coronary revascularization or AF ablation) during the TAVR procedure, within 30 days before or after the TAVR procedure
- •Emergency surgery for any reason
- •Pregnancy, lactation or intent to become pregnant during study participation
- •Unable or unwilling to complete all required screening and/or follow-up assessments, including subjects with active major psychiatric disease; with severe visual, auditory, or learning impairment
- •Investigator considers participation in the study not to be in the subject's best interest
- •Dementia or any other cognitive deficit that results in inability to provide informed consent or comply with the study protocol
- •Presence of hemodialysis shunt, graft, or arterio-venous fistula involving access vasculature
结局指标
主要结局
Non-inferiority
时间窗: Non-inferiority of 30-day Emboliner device MACCE patient incidence rate compared to the Sentinel device patient incidence rate.
Non-inferiority of 30-day Emboliner device MACCE patient incidence rate compared to the Sentinel device patient incidence rate. K4: Description Non-inferiority of 30-day Emboliner device MACCE patient incidence rate compared to the Sentinel device patient incidence rate. 30 Days
次要结局
- Non-inferiority VARC-2(30 Days)
- Debris Capture(30 Days)
研究者
研究点 (3)
Loading locations...
相似试验
招募中
不适用
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVRAortic Stenosis Treated With TAVIAortic DiseasesNCT06689839EnCompass Technologies, Inc.500
已完成
2 期
Prospective Randomized Study Comparing Renal Artery Stenting (RESIST)With/Without Distal ProtectionRenal Artery StenosisNCT00234585University of Toledo Health Science Campus100
招募中
4 期
Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar RhytidesWrinkleGlabellar Frown LinesGlabellar FurrowingNCT06448676Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)325
已完成
不适用
The Protrieve PROTECTOR StudyVenous ThromboembolismDeep Venous ThrombosisNCT06495996Inari Medical66
终止
不适用
A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive BladderUrinary Urge IncontinenceUrge IncontinenceOveractive BladderNCT05381116Avation Medical, Inc.125